Hence, the observations here that IL-15C-drives STAT3 activation in NK cells and their production of IL-10 may indicate that targeting of NK cells in this context could reduce the efficacy of anti-cancer IL-15C therapy or at least limit NK cell cytotoxicity. The gene discussed is IL10; the disease is cancer.